MetaADEDB 2.0 @ LMMD
Ciclopirox
(SCKYRAXSEDYPSA-UHFFFAOYSA-N)
Structure
SMILES
Cc1cc(C2CCCCC2)n(c(=O)c1)O
Type(s)
Approved; Investigational
ATC code(s)
D01AE14; G01AX12
Molecular Formula:
C12H17NO2
Molecular Weight:
207.269
Log P:
2.4417
Hydrogen Bond Acceptor:
3
Hydrogen Bond Donor:
1
TPSA:
42.23
CAS Number(s):
29342-05-0
Synonym(s)
1.
Ciclopirox
2.
6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone ethanolamine salt
3.
Batrafen
4.
Ciclopirox Olamine
5.
Ciclopiroxolamine
6.
Cyclopirox
7.
Cyclopyroxolamine
8.
Dafnegin-CSC
9.
HOE 296
10.
HOE-296
11.
Loprox
12.
Penlac
13.
Dafnegin CSC
14.
HOE296
External Link(s)
MeSHD000077768
PubChem Compound2749
BindingDB81379
66087
ChEBI453011
CHEMBLCHEMBL1413
DrugBankDB01188
DrugCentral636
KEGGdr:D03488
Therapeutic Target DatabaseD07GRH
ZINC1145
Adverse Drug Event(s)
NameNumber of ReportsReference(s)Data Source
1Drug ineffectiveFAERS: 39
Canada Vigilance: 29		Canada Vigilance
US FAERS
2AlopeciaFAERS: 9
Canada Vigilance: 1		Canada Vigilance
OFFSIDES
SIDER
US FAERS
3Accidental exposure to productFAERS: 5US FAERS
4Expired product administeredFAERS: 5US FAERS
5PruritusFAERS: 5
Canada Vigilance: 2		Canada Vigilance
SIDER
US FAERS
6Drug ineffective for unapproved indicationFAERS: 4US FAERS
7ErythemaFAERS: 4
Canada Vigilance: 1		Canada Vigilance
SIDER
US FAERS
8Wrong technique in product usage processFAERS: 4US FAERS
9Application site painFAERS: 3
Canada Vigilance: 1		Canada Vigilance
US FAERS
10Drug prescribing errorFAERS: 3US FAERS
11Dry skinFAERS: 3OFFSIDES
SIDER
US FAERS
12HeadacheFAERS: 3SIDER
US FAERS
13InflammationFAERS: 3US FAERS
14PainFAERS: 3
Canada Vigilance: 1		Canada Vigilance
OFFSIDES
SIDER
US FAERS
15Therapeutic response unexpected with drug substitutionFAERS: 3US FAERS
16Application site pruritusFAERS: 2
Canada Vigilance: 1		Canada Vigilance
US FAERS
17Application site vesiclesFAERS: 2US FAERS
18Inappropriate schedule of drug administrationFAERS: 2US FAERS
19NauseaFAERS: 2OFFSIDES
US FAERS
20OnychoclasisFAERS: 2US FAERS
21OnycholysisFAERS: 2US FAERS
22OnychomycosisFAERS: 2
Canada Vigilance: 4		Canada Vigilance
US FAERS
23Product quality issueFAERS: 2US FAERS
24Product use in unapproved indicationFAERS: 2US FAERS
25Product use issueFAERS: 2US FAERS
26AcneFAERS: 1OFFSIDES
US FAERS
27Application site erosionFAERS: 1US FAERS
28Application site papulesFAERS: 1US FAERS
29Application site swellingFAERS: 1US FAERS
30Blood glucose abnormalFAERS: 1US FAERS
31Burning sensationFAERS: 1SIDER
US FAERS
32CellulitisFAERS: 1OFFSIDES
US FAERS
33Cerebrovascular accidentFAERS: 1US FAERS
34Chemical burn of skinFAERS: 1US FAERS
35Drug administered at inappropriate siteFAERS: 1US FAERS
36DysgeusiaFAERS: 1OFFSIDES
US FAERS
37Exfoliative rashFAERS: 1US FAERS
38Eye irritationFAERS: 1US FAERS
39FatigueFAERS: 1OFFSIDES
US FAERS
40Foreign body traumaFAERS: 1US FAERS
41Gastrointestinal inflammationFAERS: 1US FAERS
42HypersensitivityFAERS: 1US FAERS
43Inappropriate schedule of product administrationFAERS: 1US FAERS
44Incorrect drug administration durationFAERS: 1US FAERS
45InfluenzaFAERS: 1US FAERS
46Intentional product misuseFAERS: 1US FAERS
47Joint swellingFAERS: 1US FAERS
48MalaiseFAERS: 1US FAERS
49Medication ErrorFAERS: 1US FAERS
50No adverse eventFAERS: 1US FAERS
51Oral painFAERS: 1US FAERS
52PalpitationsFAERS: 1US FAERS
53Pharmaceutical product complaintFAERS: 1OFFSIDES
US FAERS
54Product container issueFAERS: 1US FAERS
55Product measured potency issueFAERS: 1US FAERS
56Product physical consistency issueFAERS: 1US FAERS
57Product substitution issueFAERS: 1US FAERS
58Reaction to drug excipientsFAERS: 1US FAERS
59Skin irritationFAERS: 1US FAERS
60Squamous cell carcinomaFAERS: 1US FAERS
61ThrombosisFAERS: 1US FAERS
62Tongue spasmFAERS: 1US FAERS
63Unevaluable eventFAERS: 1OFFSIDES
US FAERS
64UrticariaFAERS: 1US FAERS
65VomitingFAERS: 1US FAERS
66Weight decreasedFAERS: 1US FAERS
67Wrong drug administeredFAERS: 1US FAERS
68Wrong technique in drug usage processFAERS: 1US FAERS
69Abdominal PainOFFSIDES
70Abdominal discomfortOFFSIDES
71Abnormal visionOFFSIDES
72Acid refluxOFFSIDES
73Actinic keratosisOFFSIDES
74Acute Coronary SyndromeOFFSIDES
75Acute otitis mediaOFFSIDES
76AdenitisOFFSIDES
77Adenocarcinoma21217783CTD
78Adenomatous Polyposis ColiOFFSIDES
79Administration site warmthCanada Vigilance: 1Canada Vigilance
80AgitationCanada Vigilance: 1Canada Vigilance
81Alanine Aminotransferase IncreasedOFFSIDES
82Allergy to animalOFFSIDES
83Anal FissureOFFSIDES
84Anal FistulaOFFSIDES
85Anal abscessOFFSIDES
86AnhedoniaOFFSIDES
87AnhidrosisOFFSIDES
88Ankyloglossia acquiredOFFSIDES
89AnorexiaOFFSIDES
90AnosmiaOFFSIDES
91Antinuclear antibody increasedOFFSIDES
92AnxietyOFFSIDES
93Application site hypersensitivitySIDER
94Application site irritationSIDER
95Application site rashSIDER
96Application site reactionSIDER
97ArteriosclerosisOFFSIDES
98ArthritisOFFSIDES
99Arthropod biteOFFSIDES
100AscitesOFFSIDES
101AstheniaCanada Vigilance: 1Canada Vigilance
OFFSIDES
102AstigmatismOFFSIDES
103AtherosclerosisOFFSIDES
104Atrial FlutterOFFSIDES
105Biliary dilatationOFFSIDES
106Bipolar DisorderOFFSIDES
107Blood GlucoseOFFSIDES
108Blood alkaline phosphatase increasedOFFSIDES
109Blood creatine phosphokinase increasedOFFSIDES
110Blood electrolytes abnormalOFFSIDES
111Blood glucose decreasedOFFSIDES
112Blood glucose fluctuationOFFSIDES
113Bone lesionOFFSIDES
114Bone painOFFSIDES
115BradycardiaOFFSIDES
116Brain natriuretic peptide increasedOFFSIDES
117BronchitisOFFSIDES
118BruxismOFFSIDES
119Candidiasis16640825CTD
120Central venous catheter removalOFFSIDES
121Chest PainOFFSIDES
122Choking sensationOFFSIDES
123ChondromalaciaOFFSIDES
124Clostridium difficile colitisOFFSIDES
125ColitisOFFSIDES
126Colon adenomaOFFSIDES
127Colonic Neoplasms21217783CTD
128Congenital pyelocaliectasisOFFSIDES
129CystOFFSIDES
130Delusional disorder, unspecified typeOFFSIDES
131DemyelinationOFFSIDES
132Dental abscessOFFSIDES
133Dental prosthesis userOFFSIDES
134Denture wearerOFFSIDES
135DependenceOFFSIDES
136DermatitisSIDER
137Dermatomycoses21217783CTD
138DermatomyositisOFFSIDES
139Dermoid CystOFFSIDES
140DiabetesOFFSIDES
141Diastolic dysfunctionOFFSIDES
142DiverticulitisOFFSIDES
143DizzinessCanada Vigilance: 1Canada Vigilance
OFFSIDES
144DrowningOFFSIDES
145DyspareuniaOFFSIDES
146DyspepsiaOFFSIDES
147DysphoniaOFFSIDES
148Economic problemOFFSIDES
149EczemaSIDER
150Ejection Fraction DecreasedOFFSIDES
151Emotional disorderOFFSIDES
152Emotional distressOFFSIDES
153Endodontic procedureOFFSIDES
154Endometrial HyperplasiaOFFSIDES
155Erythema NodosumOFFSIDES
156Esophageal StenosisOFFSIDES
157Eustachian tube disorderOFFSIDES
158Eye painSIDER
159Face LiftOFFSIDES
160Fatty LiverOFFSIDES
161FibromyalgiaOFFSIDES
162Flank PainOFFSIDES
163Fluid overloadOFFSIDES
164Food PoisoningOFFSIDES
165GamblingOFFSIDES
166GastroenteritisOFFSIDES
167General physical health deteriorationOFFSIDES
168GingivectomyOFFSIDES
169GlobulinuriaOFFSIDES
170GoiterOFFSIDES
171GranulocytosisOFFSIDES
172Hair discolorationSIDER
173HepatitisOFFSIDES
174HepatomegalyCanada Vigilance: 1Canada Vigilance
175HydronephrosisOFFSIDES
176HyperkeratosisOFFSIDES
177IleitisOFFSIDES
178InfectionOFFSIDES
179Joint stiffnessOFFSIDES
180LaryngoceleOFFSIDES
181Left Ventricular HypertrophyOFFSIDES
182LentigoOFFSIDES
183Limb discomfortCanada Vigilance: 1Canada Vigilance
OFFSIDES
184Limb injuryOFFSIDES
185Liquid product physical issueCanada Vigilance: 1Canada Vigilance
186Loose toothOFFSIDES
187LymphedemaOFFSIDES
188LymphomaOFFSIDES
189Malignant HypertensionOFFSIDES
190Mammary duct ectasiaOFFSIDES
191MastectomyOFFSIDES
192Mastication disorderOFFSIDES
193Maxillofacial operationOFFSIDES
194Mediastinal massOFFSIDES
195Medical device removalOFFSIDES
196Multi-organ disorderOFFSIDES
197Multiple SclerosisOFFSIDES
198NasopharyngitisOFFSIDES
199Nephritis allergicOFFSIDES
200NoduleOFFSIDES
201Oral Cavity FistulaOFFSIDES
202Oral polypectomyOFFSIDES
203OsteomyelitisOFFSIDES
204OsteopeniaOFFSIDES
205OsteoporosisOFFSIDES
206OsteoradionecrosisOFFSIDES
207PancreatitisOFFSIDES
208Pericardial effusionOFFSIDES
209Perirectal abscessOFFSIDES
210Periungual erythemaSIDER
211Polysubstance abuseOFFSIDES
212Poor personal hygieneOFFSIDES
213Posterior capsule opacificationOFFSIDES
214Primary mediastinal large B-cell lymphoma stage IIOFFSIDES
215Psychiatric symptomOFFSIDES
216Pulmonary congestionOFFSIDES
217Rash erythematousCanada Vigilance: 1Canada Vigilance
218Reflux laryngitisOFFSIDES
219Renal cystOFFSIDES
220Restrictive pulmonary diseaseOFFSIDES
221Rhabdomyosarcoma21217783CTD
222RhinorrheaOFFSIDES
223SchizophreniaOFFSIDES
224ScotomaOFFSIDES
225Secondary sequestrumOFFSIDES
226SeromaOFFSIDES
227Sick Sinus SyndromeOFFSIDES
228Sinus bradycardiaOFFSIDES
229SinusitisOFFSIDES
230Skin hypertrophyCanada Vigilance: 1Canada Vigilance
231Skin lacerationCanada Vigilance: 1Canada Vigilance
232Skin lesionOFFSIDES
233Somatoform DisorderOFFSIDES
234SomnolenceCanada Vigilance: 1Canada Vigilance
235Stevens-Johnson SyndromeOFFSIDES
236Stress ulcerOFFSIDES
237Suture insertionOFFSIDES
238SwellingCanada Vigilance: 1Canada Vigilance
239TendinitisOFFSIDES
240Toe operationOFFSIDES
241Tooth ExtractionOFFSIDES
242TracheitisOFFSIDES
243Umbilical herniaOFFSIDES
244Upper airway obstructionOFFSIDES
245Urine leukocyte esteraseOFFSIDES
246Visual disturbanceOFFSIDES
247WheezingCanada Vigilance: 1Canada Vigilance
248Wound dehiscenceOFFSIDES
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120239

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.